Harish Thakkar, MD
Internal Medicine · Sugar Land, TXNPI 1053410910
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,453 of the $22,282 with a category attached, or 73.8%. It is spread thinly across 49 manufacturers, the largest accounting for just 17.6%. Reporting peaked in 2023 at $7,937 and has fallen 74.9% since, to $1,990 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 953 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$4K
- Bayer$2K
- AstraZeneca$2K
- Novo Nordisk$2K
- Modernatx, Inc.$2K
- Dexcom, Inc.$1K
- plus $9K from 43 others
Across 424 payments — averaging $14,914 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.2M
- Astrazeneca UK Limited$1.1M
- Sanofi Pasteur Inc.$968K
- AbbVie$393K
- IBSA Institut Biochimique SA$353K
- Bavarian Nordic A/s$287K
- plus $1.1M from 14 others
What the payments were for
- Travel & lodging$5,60425%
- Food & beverage$16,45374%
- Education$2251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,282 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 163 | $264,644 |
| MounjaroTirzepatide | 214 | $255,049 |
| EliquisApixaban | 209 | $204,224 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 82 | $129,914 |
| ProliaDenosumab | 75 | $127,142 |
| VascepaIcosapent Ethyl | 117 | $107,315 |
| FarxigaDapagliflozin Propanediol | 75 | $93,959 |
| LinzessLinaclotide | 63 | $81,506 |
| TradjentaLinagliptin | 62 | $80,615 |
| XareltoRivaroxaban | 74 | $78,533 |
| JardianceEmpagliflozin | 64 | $76,556 |
| Repatha SureclickEvolocumab | 60 | $71,987 |
| GlyxambiEmpagliflozin/Linagliptin | 44 | $57,161 |
| KerendiaFinerenone | 35 | $56,156 |
| SynjardyEmpagliflozin/Metformin Hcl | 39 | $55,630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Tradjenta, Jardiance, Glyxambi, Synjardy | $797 | $473,521350 claims |
| Novo NordiskOzempic, Rybelsus | $1,833 | $298,352182 claims |
| Lilly USA, LLCMounjaro, Trulicity | $913 | $283,371232 claims |
| PfizerEliquis | $228 | $204,224209 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,182 | $149,100155 claims |
| AmgenProlia | $988 | $127,14275 claims |
| AbbVieLinzess, Namzaric | $135 | $108,74289 claims |
| MerckJanuvia, Verquvo, Janumet | $698 | $86,18961 claims |
| Johnson & JohnsonXarelto | $326 | $78,53374 claims |
| BayerKerendia | $2,476 | $56,15635 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $47,55947 claims |
| GSKTrelegy Ellipta | $406 | $46,33155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Sugar Land
- Spencer BerthelsenSugar Land$891K
- Bartley GillSugar Land$218K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.